Physician profile
Karen Abele Devore
NPI 1821098823
$15,260.09
in general payments reported to CMS, 2019-2025
36 companies · $2,563 in 2025
The $2,563 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $2,372 · 2021: $1,622 · 2022: $2,151 · 2023: $2,244 · 2024: $2,617 · 2025: $2,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,770 · Education: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,770.32 |
| Education | $653.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,001.76 | 2019-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $2,265.67 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,263.19 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $1,215.42 | 2019-2025 | |
| Ucb, INC. | $1,005.76 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $845.10 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $807.01 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $757.52 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $533.97 | 2020 | |
| Lilly USA, LLC | $507.69 | 2019-2025 | Taltz, Ebglyss |
| Incyte Corporation | $389.26 | 2022-2025 | Opzelura |
| Almirall LLC | $254.27 | 2020-2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $250.47 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $238.11 | 2019-2025 | Dupixent |
| Genzyme Corporation | $225.34 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $222.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $216.16 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $198.70 | 2020-2025 | Siliq, Cabtreo, Jublia |
| Organon LLC | $192.34 | 2023-2025 | Hadlima, Vtama |
| Revance Therapeutics, INC. | $135.98 | 2024-2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.63 | 2022-2024 | Cyltezo, Spevigo |
| Galderma Laboratories, L.P. | $101.49 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $86.83 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $85.13 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $75.95 | 2019-2023 | |
| Strata Skin Sciences, INC. | $71.30 | 2021-2025 | Xtrac |
| Dermira, INC. | $40.82 | 2020 | |
| Merz North America, INC. | $39.84 | 2022 | |
| Cipher Pharmaceuticals US LLC | $24.12 | 2025 | Spinosad, Natroba |
| Mylan Institutional INC. | $20.37 | 2023 | Hulio |
| Mylan Pharmaceuticals INC. | $19.14 | 2019 | |
| Allergan, INC. | $17.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.04 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.